Bemnifosbuvir (BEM) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
Trial Timeline
Nov 25, 2022 → May 30, 2024
NCT ID
NCT05629962About Bemnifosbuvir (BEM) + Placebo
Bemnifosbuvir (BEM) + Placebo is a phase 3 stage product being developed by Atea Pharmaceuticals for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection). The current trial status is completed. This product is registered under clinical trial identifier NCT05629962. Target conditions include Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05629962 | Phase 3 | Completed |
Competing Products
20 competing products in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)